Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michel Azizi

Showing results (41-50 of 267) with videos related to

Pageof 27
Sort By:
Current Hypertension Reports|October 14, 2020
Is there any Hope for Monitoring Adherence in an Efficient and Feasible Way for Resistant Hypertension Diagnosis and Follow-Up?Benjamin Kably, Eliane M Billaud, Pierre Boutouyrie, et al.
Journal of Hypertension|March 2, 2006
Renin inhibition with aliskiren: where are we now, and where are we going?Michel Azizi, Randy Webb, Juerg Nussberger, et al.
Journal of Hypertension|September 26, 2003
Dual renin-angiotensin system blockade restores blood pressure-renin dependency in individuals with low renin concentrationsMichel Azizi, Alvine Bissery, Alessandra Bura-Rivière, et al.
Blood Pressure|October 27, 2017
How to perform a cost-effectiveness analysis with surrogate endpoint: renal denervation in patients with resistant hypertension (DENERHTN) trial as an exampleJulie Bulsei, Meryl Darlington, Isabelle Durand-Zaleski, et al.
La Revue Du Praticien|April 3, 2020
[Hypertension, telemedicine and e-health: what to remember in practice?]Nicolas Postel-Vinay, Guillaume Bobrie, Laurence Amar, et al.
Journal of Hypertension|October 11, 2013
Can we use mineralocorticoid receptor blockade in diabetic patients with resistant hypertension? Yes we can! But it may be a double-edged swordMichel Azizi, Matthieu Monge, Aurélien Lorthioir, et al.
Presse Medicale (Paris, France : 1983)|September 2, 2019
[Spironolactone in resistant essential hypertension]Aurélien Lorthioir, Inès Belmihoub, David Fouassier, et al.
Journal of Hypertension|June 10, 2009
The lactotripeptides isoleucine-proline-proline and valine-proline-proline do not inhibit the N-terminal or C-terminal angiotensin converting enzyme active sites in humansGrégoire Wuerzner, Séverine Peyrard, Anne Blanchard, et al.
Lancet (London, England)|October 14, 2015
Renal denervation for resistant hypertension - Authors' replyMichel Azizi, Helena Pereira, Guillaume Bobrie, et al.
Fundamental & Clinical Pharmacology|November 3, 2011
Targeting the aldosterone pathway in cardiovascular diseaseFinn Gustafsson, Michel Azizi, Johann Bauersachs, et al.
Pageof 27

Showing results (41-50 of 267) with videos related to

Sort By:
Pageof 27
Current Hypertension Reports|October 14, 2020
Is there any Hope for Monitoring Adherence in an Efficient and Feasible Way for Resistant Hypertension Diagnosis and Follow-Up?Benjamin Kably, Eliane M Billaud, Pierre Boutouyrie, et al.
Journal of Hypertension|March 2, 2006
Renin inhibition with aliskiren: where are we now, and where are we going?Michel Azizi, Randy Webb, Juerg Nussberger, et al.
Journal of Hypertension|September 26, 2003
Dual renin-angiotensin system blockade restores blood pressure-renin dependency in individuals with low renin concentrationsMichel Azizi, Alvine Bissery, Alessandra Bura-Rivière, et al.
Blood Pressure|October 27, 2017
How to perform a cost-effectiveness analysis with surrogate endpoint: renal denervation in patients with resistant hypertension (DENERHTN) trial as an exampleJulie Bulsei, Meryl Darlington, Isabelle Durand-Zaleski, et al.
La Revue Du Praticien|April 3, 2020
[Hypertension, telemedicine and e-health: what to remember in practice?]Nicolas Postel-Vinay, Guillaume Bobrie, Laurence Amar, et al.
Journal of Hypertension|October 11, 2013
Can we use mineralocorticoid receptor blockade in diabetic patients with resistant hypertension? Yes we can! But it may be a double-edged swordMichel Azizi, Matthieu Monge, Aurélien Lorthioir, et al.
Presse Medicale (Paris, France : 1983)|September 2, 2019
[Spironolactone in resistant essential hypertension]Aurélien Lorthioir, Inès Belmihoub, David Fouassier, et al.
Journal of Hypertension|June 10, 2009
The lactotripeptides isoleucine-proline-proline and valine-proline-proline do not inhibit the N-terminal or C-terminal angiotensin converting enzyme active sites in humansGrégoire Wuerzner, Séverine Peyrard, Anne Blanchard, et al.
Lancet (London, England)|October 14, 2015
Renal denervation for resistant hypertension - Authors' replyMichel Azizi, Helena Pereira, Guillaume Bobrie, et al.
Fundamental & Clinical Pharmacology|November 3, 2011
Targeting the aldosterone pathway in cardiovascular diseaseFinn Gustafsson, Michel Azizi, Johann Bauersachs, et al.
Pageof 27